Sameem Abedin
Medical College of Wisconsin
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Sameem Abedin as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:11 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07808112 · CSF-1R Inhibitor, Axatilimab, for Prevention of Acute and Chronic GVHD After HLA-Matched Related and Unrelated Donor Allogeneic Stem Cell TransplantationMedical College of Wisconsin · not yet recruiting · Graft -Versus-host-disease · principal investigator
- Ph2NCT07572929 · A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic TransplantMedical College of Wisconsin · not yet recruiting · Myeloid Disorders, Myelodysplastic Syndromes, Myeloproliferative Neoplasm · principal investigator
- N/ANCT05802069 · MCW Master Predict (Profile Related Evidence Determining Individualized Cancer Therapy)Sameem M. Abedin, MD · recruiting · Cancer · principal investigator
- Ph2NCT05622318 · De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) ProphylaxisMedical College of Wisconsin · active not recruiting · Graft-versus-host Disease · principal investigator
- Ph1NCT04144036 · Neihulizumab for Standard-Risk Acute Graft Versus Host Disease (GVHD)Sameem M. Abedin, MD · completed · Graft-versus-host Disease · principal investigator
- Ph1NCT03848754 · Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid LeukemiaMedical College of Wisconsin · completed · Relapsed Adult AML · principal investigator
- Ph1NCT03441048 · Lintuzumab-Ac225 in Combination with Cladribine + Cytarabine + Filgastrim + Mitoxantrone (CLAG-M) for Relapsed/Refractory Acute Myeloid LeukemiaMedical College of Wisconsin · completed · Acute Myeloid Leukemia · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:11 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in acute myeloid leukemia, ranked by citations from NIH iCite, fetched 2026-11-12 10:11 UTC. The ranking covers the 200 most relevant of 3 PubMed records, and a shared surname and initials can bring in a namesake. All 3 on PubMed
- A phase I study of pevonedistat, azacitidine, and venetoclax in patients with relapsed/refractory acute myeloid leukemia.Haematologica · 202421 citationsRCR 2.9
- Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed/refractory acute myeloid leukemia.Leukemia · 202512 citationsRCR 2.5
- A phase 1 study of the CDK9 inhibitor voruciclib in relapsed/refractory acute myeloid leukemia and B-cell malignancies.Blood Adv · 20259 citationsRCR 2.3